 |
 |
 |
|
The
HIV/AIDS eNews is published by the British Columbia Persons With AIDS
Society. This publication is a compilation of various articles
collected from numerous news sources. Opinions and information
expressed are those of the individual authors and not necessarily those
of the Society.
|
|
|
|
Senior's Care

|
Send a Message to Premier Cambell today and help the BCHC reach its goal of sending 5000 letters to the Premier!
BC's seniors and people with disabilities deserve high-quality and accessible public health care.
Take action now and send a letter to the provincial government demanding that it make critical changes to improve the lives of BC seniors and people with disabilities. |
|
|
|
BC's Big Opt Out
BC’s Big Opt Out urges British Columbians to protect their right to privacy by refusing their personal health information be subject to eHealth, the BC Government’s new system of integrated electronic health records.
Visit their website www.bcoptout.ca to learn more about eHealth and what you can do about it. |
|
|
VOLUNTEER RECEPTION
BCPWA invites our volunteers to the South Pacific: A Night in the Tropics! This year's volunteer appreciation party is all about grass skirts, songs and sarongs.
When: 6-9.30pm, Thursday April 30
Where: Holiday Inn & Suites (1110 Howe at Helmcken)
Tickets: $10 deposit for volunteers, $25 flat-rate for friends of volunteers.
For more information, contact Marc at 604.893.2298 or marcs@bcpwa.org |
|
|
|
WEDNESDAY NIGHT SUPPORT GROUP
The Wednesday evening group welcomes people living
with HIV disease, people who are co-infected with Hepatitis C, as well
as family, friends, medical or social supports of group members. The
group focuses on mutual support, empowerment, and information exchange.
Date: Every Wednesday Evening
Time: 7:00pm - 9:00pm
Location: The Lounge - 2nd Floor
Address:1107 Seymour Street, Vancouver |
|
|
For more info, click here, or call 604.893.2259. |
HEALING RETREAT
Healing retreats for HIV-positive men and women. Join HIV-positive
people from all walks of life.
Date: June 26 - 29, 2009 and September 4 - 7, 2009
Location: Loon Lake [ Map ]
Registration: Register at reception
To book an interview:
Phone: 604.893.2200
Toll Free: 1.800.994.2437 ext. 200
Bring this completed form. |
|
|
For more info, click here.
|
Do You Need Better Access to Information on HIV/AIDS Treatment?
Then participate in a survey!
You can help BCPWA by participating in a research project to assess the changing treatment information needs of HIV-positive people in BC. The research examines the experiences that HIV-positive people have with access to HIV/AIDS treatment information and the quality of these experiences.
To access the questionnaire, go to:
http://infopoll.net/live/surveys/s33258.htm |
|
FitOne - An Introduction to Active Living
Designed for individuals seeking a more active lifestyle, FitOne aims to educate participants about the beneficial effects of exercise on HIV disease while creating a mutually supportive and motivating environment.
Intended for all fitness levels, a certified kinesiologist will assess and design programs suited for individual needs. Yoga mats and exercise equipement provided. Comfortable cloths and exercise shoes recommended. Beginners welcome.
Activities may include group walks, running clinics, and beginner's yoga. |
 |
Weekly sessions begin Wednesday, February 25, 2009 from 3 – 4pm in the BCPWA Training Room
For more information, please contact elginl@bcpwa.org or call 604.893-2225. Limited number of participants. Register now. |
|
|
SUITS
Join us at our next monthly networking event for professional, gay HIV+ men!
Where: Fraser Downs Racetrack
When: Saturday, May 2, 6:30-11:00PM
RSVP: (required) 604.893.2258
For more information call 604.893.2200 |
|
|
|
SPIRITUAL WORKSHOP
Non-denominational, supportive, unique and fun.
Join other HIV+ men and women, lakeside at the Bethlehem Retreat Centre on Vancouver Island for a 3-night/ 4 day workshop devoted to personal spirituality. A provocative, progressive workshop created on the teachings of Mathew Fox. People come away renewed with a sense of hope, a feeling of global community and a boost to their self-esteem.
|
|
Workshop designed and facilitated by United Church Ministers, Rev. Tim Stevenson, and spouse Rev. Gary Paterson, Minister St. Andrew's Wesley United Church. Taking time to laugh and to listen, their knowledge and kindness enhances learning and garners trust.
Organized by BCPWA Retreat Team.
Lodging and meal hosted by the Benedictine Sisters.
Transportation provided.
Spaces go quickly.
Interviews March 2-April 10, 2009.
Register for an interview 604.893.2200 or 1.800.994.2437. |
|
|
|
 |
Survey on Employment Issues for People Living with HIV/AIDS
People living with HIV are invited to participate in an online survey on HIV and employment in Canada. The purpose of this survey is to learn more about the education, training, employment and health needs of people living with HIV. Our ultimate goal is a national network that will provide employment support, information and advocacy opportunities for people living with HIV whether in or out of the workforce. Your responses to the survey will inform us on the employment-related issues that matter to you most.
The survey is available electronically and will take approximately 25 minutes to complete. You will be able to save survey responses and then submit the final version at a later date. If you would like to request a hardcopy of the survey please send your contact information to the address below.
You do not have to give personal information and we do not plan to publish personal information. If this plan changes, we will only do so with your agreement. You have the right to opt out of any question(s) at any point throughout the survey. You may choose to provide us with contact information if you would like to be kept updated on the progress of this project.
The link to the survey is provided below. The survey will be open for responses through Friday, March 13. This opportunity is unique to people with HIV. We look forward to your response to the survey.
http://www.surveymonkey.com/s.aspx?sm=BxPMtNFSCtrk5n1CZTiWPQ_3d_3d
|
Cut ties between Health Canada, drug companies, grieving MP urges
Young
is seeking an independent drug agency that gets no money from the
pharmaceutical industry and is focused on keeping Canadians safe when
using prescription drugs. It would be similar to the Transportation
Safety Board.
April 20, 2009

Vanessa Young was taking a medication called Prepulsid when she died suddenly at age 15.
A
federal Conservative MP whose 15-year-old daughter collapsed and died
after taking a prescription medication will this week introduce a
private member's motion calling for an arm's length drug safety agency.
Vanessa Young died in a hospital in Hamilton, Ont., in March
2000. Her father, Oakville MP Terence Young, believes a medication
called Prepulsid or cisapride prescribed by their family doctor
contributed to her death.
"She jumped up to go upstairs and
fell down in front of me," Young recalled on CBC Radio's Metro Morning
on Monday. "Her heart stopped dead."
At the hospital, doctors
repeatedly asked the family who prescribed the drug. It was given to
Vanessa to treat her mild form of bulimia, which sometimes caused her
to feel bloated after eating.
As one of the doctors left the
hospital the next day after Vanessa died, Young asked the doctor about
the drug. The doctor's response — "Well, they dish it out like water" —
led Young to start investigating adverse drug reactions.
Adverse
reactions cause 10,000 deaths a year in Canadian hospitals when drugs
are used as prescribed, Young said. Probably another 10,000 deaths
occur outside of hospitals from prescribing errors and adverse
reactions, he added, noting less than one per cent of reactions get
reported.
'Pray that I'm persuasive'
"It's kind of a dream
for me to be in the Parliament of Canada because those of us who worked
on prescription drug safety for such a long time, we were in the
wilderness," said Young, who is also the author of a new book called
Death By Prescription.
"I can go directly to the decision-makers and I pray that I'm persuasive."
Young
is seeking an independent drug agency that gets no money from the
pharmaceutical industry and is focused on keeping Canadians safe when
using prescription drugs. It would be similar to the Transportation
Safety Board.
Young outlined several issues he has with drug safety in Canada, including:
- Official prescribing information documents for doctors that run to 50
pages of fine print, leading many physicians to rely on drug sales
representatives for their information.
- Changes in Health Canada's mandate dating to 1997 that ordered the
department to partner with pharmaceutical companies to help them market
their drugs.
- A lack of independent checks into the safety of prescribed drugs.
- Pressure on Health Canada's drug reviewers to get drugs to market
faster, since pharmaceutical companies pay for 60 per cent of drug
reviewers.
- Pharmaceutical company safety information is considered a commercial
secret by Health Canada, as opposed to the U.S. Food and Drug
Administration that makes the information available on the internet.
Health
Canada reviewers "view themselves as helping the companies sell drugs,
which in many cases is the antithesis of public health," Young said.
Also
Monday, pharmaceutical industry critic Dr. Joel Lexchin said Health
Canada's approach to drug regulation puts too much emphasis on speeding
up drug approvals and not enough on checking the safety of drugs
already on the market.
Lexchin, who teaches at Toronto's York
University, said Health Canada can't make a drug company recall
medications from store shelves or compel a company to change safety
labels on approved drugs.
Health Canada said Lexchin's
critique doesn't take into account the department's recent efforts to
track drug safety after a product has been approved.
The
regulator has the authority to withdraw a drug's licence, which means
companies generally comply with requests to change drug labelling, said
Dr. Marc Berthiaume, director of Health Canada's marketed
pharmaceuticals and medical devices bureau.
Last year, Health
Canada told CBC News that its mandate is to bring additional safety
information to the prescriber, but the way doctors handle that
information is part of their professional autonomy.
Prepulsid was pulled from the market in Canada in August 2000.
http://www.cbc.ca/
|
B.C.'s AIDS heroes honoured at AccolAIDS 2009
April 20, 2009
Last night, the hardworking heroes of B.C.'s AIDS movement were
recognized and celebrated with awards at the eighth annual AccolAIDS
gala, held at the Fairmont Hotel Vancouver.
Vancouver's First
Lady of Glam, Symone, entertained the audience in style with musical
numbers from Diana Ross and also hosted the evening
While
attendees enjoyed a four-course dinner, flowing bottles of wine, and a
jovial atmosphere, there were also poignant moments, a few tears, and
heartfelt messages about the current state of HIV and AIDS in British
Columbia.
The PHS Community Services Society won the first
award of the evening, in the category of Social/Political/Community
Action. David Eby of the Pivot Legal Society, armed with a tambourine,
presented the award by turning his presentation speech into a rap
(resulting in much laughter). PHS has helped people living in
Vancouver's Downtown Eastside since 1993.
The philanthropy
award went to Kim Osborne, founder of Chefs for Life, which has raised
more than $700,000 in funds for the Vancouver Friends for Life Society,
a non-profit wellness centre for individuals with life-threatening
diseases.
In the media category, there was only one nominee:
Xtra! West. Editor Robin Perelle accepted the award with columnist Tony
Correia, who chronicles his life with HIV in the newspaper. Perelle
pointed out that much of the mainstream media's attention focuses on
the criminalization of HIV, but fails to investigate why some people
with HIV continue to feel the need to conceal their status. Correia
added that while HIV status is often asked, the feelings of those
living with HIV are often not inquired about.
Boys 'R' Us won
the Health Promotion and Harm Reduction award. The organization was
created to fill in the lack of services available for male and
transgendered sex workers.
Dr. Mark Tyndall, one of the
foremost experts on HIV, won the Science/Research/Technology award.
Tyndall has researched HIV care for intravenous injection drug users
and marginalized populations, and worked in Africa as well as the
Downtown Eastside.
Vancouver's Maximally Assisted Therapy
Program won the Innovative Programs & Service Delivery Award. The
MAT Progam helps Downtown Eastside HIV–positive individuals with access
and adherence to antiretroviral therapy.
The Kevin Brown PWA
Hero Award went to the chair of the board of directors for the Positive
Women's Network, Kath Webster. Webster has worked as part of BCPWA's
Treatment Information Program, conducted Body Mapping workshops,
volunteered for the AIDS Walk For Life for a decade, and is involved
with the Pacific AIDS Network.
The Unsung Heroes Award was
posthumously awarded to Andrew (AJ) Johnson. Among Johnson's extensive
list of work in the field of AIDS and HIV, he worked as executive
director of AIDS Vancouver; worked at the Dr. Peter Centre, Vancouver
Community College, and St. Paul's Hospital; and was a founding member
of the Canadian Association of Nurses in AIDS Care.
Over the
course of the evening, funds from a silent auction and a live auction
(conducted by CBC's hilarious Fred Lee) totaled a record amount of
$102,840.
The evening was presented by the BC Persons With AIDS Society and GlaxoSmithKline in partnership with Shire Canada.
By Craig Takeuchi, http://www.straight.com/
|
Government of Canada Announces Renewed Support for Canadians Volunteering Overseas
The
Honourable Beverley J. Oda, Minister of International Cooperation,
today met with senior representatives of Canadian Volunteer Cooperation
Agencies (VCAs) and marked National Volunteer Week by announcing the
renewal of the Volunteer Cooperation Program over 5 years.
April 22, 2009
Ottawa - The Honourable Beverley J. Oda, Minister of International
Cooperation, today met with senior representatives of Canadian
Volunteer Cooperation Agencies (VCAs) and marked National Volunteer
Week by announcing the renewal of the Volunteer Cooperation Program
over 5 years.
"Canadians have always volunteered to improve the lives of those
living in poverty around the world. This reflects the best of our
Canadian values." Minister Oda said. "I am pleased that the renewal of
the Volunteer Cooperation Program, with the help of Canadian NGO
partners, means Canadians will continue to contribute their diverse
experience to help those in developing countries."
The Volunteer Cooperation Program will help leverage the skills and
expertise of volunteers across sectors, including fighting HIV/AIDS,
malaria and other diseases; promoting economic growth and
self-reliance, education and training programs. The additional support
will allow the volunteer cooperation agencies to increase the number of
volunteers from approximately 2,500 to 8,500.
"Canadian volunteers are Canada's ambassadors, often living in
remote villages and rural communities, working side by side with the
people they have gone to assist," added Minister Oda.
The government of Canada is committed to delivering aid that is
effective, focused and accountable. CIDA will work with the Volunteer
Cooperation Agencies to ensure the number of volunteers is maximized
over the course of the next 5 years, to meet the volunteer placement
targets.
Backgrounder:
Canada Committed to Supporting Overseas Volunteer Cooperation
The Government of Canada has renewed the Volunteer Cooperation
Program that provides ongoing financial support to the Canadian
volunteer cooperation agencies.
The Canadian International Development Agency (CIDA) will provide
$244.6 million over five years, a significant increase over the $42
million that was provided between 2004 and 2009. The funds will support
eight programs managed by nine volunteer cooperation agencies.
Approximately half of the current programming is carried out in Africa
and one-third in the Americas.
The program will leverage the skills and expertise of an estimated
8,500 volunteers. The volunteer cooperation agencies aim to define and
meet local needs through placements of qualified volunteers and
volunteer-exchange programs. By engaging a large and diverse spectrum
of Canadian volunteers, these agencies promote a better understanding
of international development issues to the Canadian public. Through
their strong connection to communities in developing countries, the
agencies are also well placed to identify emerging priorities and offer
innovative programming.
A mid-term evaluation of the Volunteer Cooperation Program was
completed in 2007, confirming that Volunteer Cooperation Program is
making a significant positive contribution to development in partner
countries. Over the course of the current program, there has been
strong collaboration amongst volunteer agencies. In West Africa, they
worked together on a shea butter marketing and production project. A
similar initiative focused on HIV/AIDS and involved partners from
across Africa and Canada. In Canada, agencies have developed a joint
website and organized training and educational events together.
CIDA, http://www.marketwire.com
|
Top court ends government pot monopoly
Canadians
who are legally permitted to smoke pot to treat illness won a victory
in the Supreme Court of Canada on Thursday when it refused to hear an
appeal of a ruling that put an end to the federal government monopoly.
April 23, 2009
The
federal government has been under pressure to clarify the rules around
medical marijuana use in public. One recent request for clarification
came from a bar owner in Burlington, Ont.,
who faced allegations of discrimination when he asked a medical marijuana user not
to smoke outside his business.
Photograph by: Mark Blinch, Reuters
OTTAWA
— Canadians who are legally permitted to smoke pot to treat illness won
a victory in the Supreme Court of Canada on Thursday when it refused to
hear an appeal of a ruling that put an end to the federal government
monopoly.
A three-judge panel, without giving reasons, rejected
the Justice Department's application to challenge a Federal Court of
Appeal decision that gave licensed producers the right to grow
marijuana for more than one patient.
The Supreme Court's
decision to stay out of the matter effectively upholds the 2008 ruling,
which dismissed the government's argument that the industry would be
thrust into deregulation if the court loosened federal restrictions.
The
decision was a victory for a group of patients who challenged the
federal regulations, arguing that the government-issued pot, supplied
by Prairie Plant Systems in Manitoba, is too weak and that they should
have the option to find their own supply.
The appeal court
decision struck down government regulations that authorized users who
cannot grow their own marijuana to designate a grower, or obtain
government-issued weed.
The patients sought the right to buy
marijuana from Carasel Harvest Supply Corp., which, under the current
regime, was not allowed to supply more than one patient with medical
marijuana.
There are about 2,000 people legally allowed to use
marijuana for medical purposes, but the lower court found only 20 per
cent buy it from the government supplier.
Justice Department
lawyer Sean Gaudet argued in the appeal court that statistics weren't
enough to conclude the government-supplied marijuana was inadequate, or
forced people to seek drugs on the black market.
Moreover,
sanctioning growers to supply more than one patient would allow the
industry to develop "without safeguards" and exacerbate the risk that
marijuana will be diverted to improper use, he said.
By Janice Tibbetts with files from Jordana Huber, http://www.theprovince.com
|
U.N.: Prisons Are Creating an HIV Time Bomb
Around
30 million people globally are incarcerated at any given time, and HIV
is a severe problem in prisons, according to UNODC. If prisons are a
reflection of society as a whole, “we are seeing a disaster around the
world,” said Costa.
April 17, 2009

On
Thursday, the head of the United Nations Office on Drugs and Crime
(UNODC) warned the spread of HIV through drug use in prisons around the
world is a “health bomb.” When infected inmates are released, they pose
a risk to the communities they return to, Antonio Maria Costa told
Reuters.
Around 30 million people globally are incarcerated at any given time,
and HIV is a severe problem in prisons, according to UNODC. If prisons
are a reflection of society as a whole, “we are seeing a disaster
around the world,” said Costa.
Prison overcrowding is a serious problem, especially in Africa and
Central America. Some prisons in these regions house up to 10 times the
number of inmates they were built for, said UNODC. One facility Costa
visited in Port-au-Prince, Haiti, was built for 420 prisoners but
contained around 4,000. Inmates there had to stand because the cells
were so crowded and had nowhere to sleep, he noted.
Costa said countries should follow U.N. guidelines on how prisons
should be run and how inmates should be treated. In addition, the
problem of overcrowding can be eased by alternative punishments for
minor crimes, he said.
http://www.hivplusmag.com
|
Fight against syphilis, AIDS goes online
As
life moves to the Internet, a growing number of public health agencies
are signing on to social networking sites — not to find friends but to
fight syphilis, AIDS and other sexually transmitted diseases.
April 18, 2009
Cincinnati
- As life moves to the Internet, a growing number of public health
agencies are signing on to social networking sites — not to find
friends but to fight syphilis, AIDS and other sexually transmitted
diseases.
Public agencies in Ohio are among the latest to open
accounts on online meeting sites in an effort to reach people who may
have a sexually transmitted disease and need medical care.
Cleveland's
health department opened accounts on two sites this week, and
Cincinnati has plans to start an online effort in a couple of months.
Columbus Public Health established a presence a year ago on Manhunt, a
social networking site for gay men, and has since added other popular
sites.
Debra Mullen, who handles online notifications for
Columbus Public Health, contacted a man a year ago who did not know he
had syphilis. She heard from him again this week.
"He got treatment and now is asking whether he needs any follow-up," she said.
Traditionally,
health departments have used letters and telephone calls to set up
preferred face-to-face meetings with the partners of infected people
who visit their clinics, test positive for a sexually transmitted
disease, and reveal their partners' names to health officials.
But
with the Net, the encounters may occur between people who know only
each other's online names. Even with that small piece of information,
health officials can go to the site, send a message to someone's
partner, and advise him or her to contact health officials and provide
contact information.
Daniel Pohl of Howard Brown Health Center
in Chicago recalls two instances where online notification has done
more good than expected.
"One client I was in contact with over
a couple of months was an escort. I was able to get him to come in for
syphilis testing, and he was infected," said Pohl, the center's manager
of disease intervention services. "He was treated for that, but was too
afraid to get tested then for HIV."
Over time, the man agreed
and tested positive for HIV a year or so ago when he was 19, Pohl said.
"He not only became very involved with his own care, but also got
involved with a program that helps other young people with HIV."
Pohl
said another man who lived with an emotionally abusive male partner was
notified and tested negative for HIV and syphilis, but agreed to see a
counselor in the center's domestic violence program.
"Sometimes
the person on the other end of the e-mail may be completely isolated
from support services, and this may help them in many ways," Pohl said.
The
National Coalition of STD Directors, consulting with the Centers for
Disease Control and Prevention, developed guidelines in 2007 to help
public health departments create profiles for confidential online
notification. Health officials say the notification cost is minimal — a
few thousand dollars for a computer and DSL line dedicated to the
program.
Rachel Kachur, a researcher with the CDC's STD
prevention division, said she is encouraged more health departments are
moving to online notification, but the work is not happening fast
enough.
"The national guidelines help by giving local areas a
jumping off point where they can tweak them to fit their needs," she
said. "But the goal is to get everyone doing this."
Health
departments in San Francisco, Washington, D.C., and Massachusetts were
among the first to begin using social networks to reach a possibly
infected person. The Web sites typically used cater to gays and
bisexuals, such as Manhunt and Adam4Adam, but some officials hope to
eventually reach the heterosexual population as well.
Cleveland,
which has seen a rise in syphilis, started a presence on Manhunt and
Adam4Adam this week, said David Merriman, project coordinator
overseeing HIV/AIDS services for the city.
"Our goal is to also
be on sites like Facebook where we could reach broader populations,
including heterosexual adults and adolescents who wouldn't use sites
like Manhunt," Merriman said.
In Massachusetts, the state health
department has reported a good response since initiating partner
notification on Manhunt in 2006. Kevin Cranston, director of the
department's infectious diseases bureau, says well over 50 percent of
those the agency contacted online responded, with some getting
department-documented medical evaluation and treatment and others
saying they would seek medical evaluation on their own.
By Lisa Cornwell, The Associated Press, http://www.google.com
|
Young, Positive and Homeless
Efforts
to provide care for HIV-positive youth work best with a full range of
services, so the program is not stigmatized as HIV-specific. Homeless
LGBT youth are at such high risk of HIV infection because of the
catastrophic merging of risk factors that homelessness adds to their
lives. Addressing their homelessness is an important first step toward
HIV testing and care. The terrible lack of safe and appropriate
emergency housing for homeless LGBT youth is a public health crisis
that we must address if we ever hope to stem the spread of HIV.
Winter 2008/2009

To
understand the impact of homelessness on youth and HIV, we turned to
two New York City experts with hands-on experience. Kate Barnhart is
the former Director of Sylvia's Place, an emergency shelter for
lesbian, gay, bisexual, and transgender (LGBT) youth, and Carl
Siciliano is the Executive Director of the Ali Forney Center, which
provides housing and supportive services to homeless LGBT youth.
How widespread is the problem?
Carl:
Nationally, a 2002 estimate found close to 1.7 million homeless and
runaway youth, most between the ages of 15 and 17. Just about 6% of
them identified as LGBT. The New York City Council recently counted
over 3,000 homeless youth in the city, and a third of them are LGBT.
Homeless youth in general are at greater risk for HIV than their peers,
and homeless LGBT youth are at particular risk. The National Coalition
for the Homeless estimates that the rate of HIV infection is 3% to 20%
higher among the homeless.
Kate: Homeless youth have a higher
risk of getting HIV because many turn to "survival sex" at some point.
Whether they're having sex for money, drugs, or a place to stay,
they're often not in a position to demand a condom. A large number have
lived with older sexual partners. Although they may consider these
relationships romantic, being dependent on another person for housing
makes them vulnerable, especially when it comes to safer sex. We have
had several cases of young people who lived with older "boyfriends" who
demanded unsafe sex, only to discover the partners' HIV status later,
by finding things like medication or ADAP cards.
Carl: Many
survive through sex work. Even those who don't do sex work tend to have
many sexual partners. Studies show that LGBT homeless youth have higher
rates of substance use. They also suffer from higher rates of mental
illness, and experience more violence and trauma. These factors create
a perfect storm of risk factors. In fact, about 25% of the clients
receiving emergency housing and drop-in services at our center are
known to have HIV.
Does just being homeless increase their risk of getting HIV?
Carl:
Being homeless increases the instability of their lives, and there are
fewer than 100 beds available to this population in New York City. So
LGBT youth find themselves in a fearful, chaotic situation that makes
it very difficult to cope with a positive test result. It seems very
clear that the lack of safe emergency housing is the greatest cause of
their high rate of HIV. Unstable housing is also the greatest barrier
to their learning their HIV status and responding in a healthy manner.
Kate:
Homeless young people are also likely to use drugs and alcohol. This
increases the risk of getting HIV, whether directly, through shared
needles, or indirectly, by removing inhibitions and impairing
decision-making skills.
Homeless transgender youth face other
risk factors. Since they lack the stability and resources needed to
make their gender transition under a doctor's care, they may turn to
street sources for hormones and silicone, and may inject them with
unclean syringes.
All of these risks can be lowered by using
harm reduction methods, but this requires education. Since many
homeless adolescents drop out of school, whether because of the
homelessness itself, anti-gay/anti-trans harassment, or for other
reasons, school-based HIV education may not reach them. Most youth
shelters and drop-in centers offer HIV testing and education, but this
only reaches those who use these services.
Do we need more HIV testing efforts?
Carl:
It would stand to reason that these young people should be tested. But
they often view testing with fear and anxiety. I recall a young
homeless trans woman who asked for an HIV test. When we did pre-test
counseling, she said that if she got a positive test she would kill her
boyfriend, who she thought infected her. We didn't test her, but
instead offered her mental health counseling. Well, she went to another
test site, found out she was HIV positive, and came back to our center
and stabbed her boyfriend. Luckily, he was not seriously injured.
Kate:
Far from lacking access to HIV testing, homeless youth are, in my
opinion, over-tested. According to our intake database, 95% of our
clients report that they've been tested recently. Many get tested
several times each month, which does not make much sense medically but
does makes sense for someone who needs an incentive like a subway fare
card.
Incentives bring other problems, too. A young person
focused on getting one may not be thinking of the possibility of
testing positive. One young man at our shelter took an HIV test to get
$5 for lunch money, tested positive, and tried to hang himself in our
bathroom that night. This is an example not only of the potential
problems of incentives, but also of the lack of follow-up services for
those who do test positive.
Carl: Even after pre-test
counseling, three of the last ten people to test positive here were
hospitalized because of a desire to commit suicide. This is clear
evidence of the need to link HIV testing with mental health counseling.
Testing is dangerous without establishing trust, and that means
addressing more pressing issues like homelessness first. Providing a
sex-positive environment that is accepting and confidential builds a
sense of community and trust. For example, one of our clients, A.J.,
was kicked out of his mother's house because of his sexual orientation.
He turned to sex work to support himself and began binge drinking to
cope with depression. After bed-hopping for some time, he heard of the
Ali Forney Center and came in for an intake.
A.J. was tested
for HIV within a month of his arrival and found out he was positive. We
were able to provide housing and primary care, along with mental health
counseling. But while he had stable housing and access to regular
health care, A.J. would fall out of mental health therapy frequently.
He was battling depression and still occasionally did sex work. He was
not disclosing to family, friends, or sex partners.
After many
discussions with us, he restarted mental health therapy, and this time
stuck with it. He developed new coping skills for his depression. After
time, he also began to accept his HIV diagnosis and was able to start
to disclose to important people in his life. Two years after learning
his diagnosis, A.J. now has permanent housing, adequate health care,
and a job. He still goes to therapy, and discloses to his sex partners.
So testing doesn't help unless young people get the services they need. Are those services available?
Kate:
While there are several excellent programs for young people with HIV,
connecting our clients with these programs takes work, like convincing
them to attend, getting their documents (many homeless youth lack birth
certificates, Social Security cards, etc), completing referral
paperwork, and escorting them to the first appointment, at least. And
while they wait to be accepted, the shelter or drop-in program must do
the work of supporting them through the initial crisis, even though
these programs often do not receive funding for these services.
There
is an urgent need for services that can be obtained quickly, with
little or no documentation, on a walk-in basis. Walk-in services are
especially needed for mentally ill and substance-using youth, and those
involved in sex work. These individuals often have great difficulty
keeping appointments due to the chaotic nature of their daily lives and
the lack of basic items like watches, appointment books, calendars, or
alarm clocks. If you're sleeping on the subway, it can be difficult to
know what day it is, never mind what time it is. And homeless young
people who are aware that they have an appointment frequently do not
have the subway fare to get there. Services for homeless youth are most
successful when provided where they gather, or within walking distance.
Is it possible for a homeless young person to get good medical care?
Kate:
They do have difficulty obtaining medical care in a consistent manner.
They often rely on emergency rooms or see medical providers only
haphazardly -- a medical van one week, the doctor at a shelter the next
-- depending on what program they are currently attending.
Adherence
to medication is also a huge issue for homeless youth. It's hard for a
young person in a shelter to take medication confidentially, since
residents may be required to give medication to staff for safekeeping
or may be seen by peers. Some meds require refrigeration, with often
only a shared refrigerator available. Young people living on the street
or moving from place to place may have their possessions stolen,
including medications that are very difficult to replace.
Carl:
Access to emergency housing is critical in getting clients to a place
where they can accept a positive test result and stay in care. Housing
provides a way to reduce continued harm from sex work and drug use by
giving them much more stability in their lives. It's clearly linked
with better health outcomes for people with chronic illnesses. It is
the bedrock on which access to care, HIV treatment, and entry into the
job market are built.
Kate: We recently had a young man
disappear from a shelter, leaving behind his medications. By the time
he returned (he had been staying with a man he met in a bar), he had
missed so many doses that it was necessary to change him to a new
regimen. Medication side effects can be especially difficult for
homeless kids since they lack easy access to bathrooms and must rely on
public restrooms or share a shelter bathroom with many others. Also,
most youth shelters require clients to be out of bed by a certain time
and are closed during the day, so there is no opportunity for rest if
needed.
How do they deal with disclosure?
Carl: Many
LGBT youth experience rejection when they come out about their
sexuality. They sometimes end up homeless as a result. And those with
HIV find it hard to disclose their status, often for the same reasons
that kept them from getting tested. It comes as no surprise that many
are afraid of yet another layer of rejection. HIV is still heavily
stigmatized, and disclosure comes with great risks. For example, family
and friends often find it hard to cope with such news, and turn to
others for comfort. Too often, news spreads quickly and youth find
themselves betrayed and full of shame.
Family and friends
often incorrectly expect that simply being LGBT will lead to HIV
infection, and HIV is still misunderstood as a death sentence. Young
people with HIV often feel like they let themselves and their loved
ones down at a time when their spirits need lifting. And these young
people not only have to deal with rejection and homelessness, but many
are born in low-income neighborhoods with high crime rates. They may
already have a fatalistic sense of what the future brings. Testing HIV
positive turns an already bleak vision of one's future into "doom."
How does having HIV affect their self-esteem?
Kate:
A large majority of our clients experienced childhood sexual abuse or
rape. This is a documented risk factor for later HIV infection, since
it can reduce personal boundaries and sense of self-worth. Self-worth
among homeless youth is also negatively affected by other traumatic
experiences, including emotional and physical abuse in childhood, death
of caretakers, homophobic and transphobic harassment, violence on the
street, and police brutality. Homeless young people are frequently
arrested for offenses ranging from sleeping in public places to more
serious crimes, and they are at risk for being raped in jail --
particularly transgender women, who are housed in male units.
Carl:
As we mature, we tend to gain ego strength and a sense of self that
comes from who we know ourselves to be. Teens are less likely than
adults to have gained this ego strength. They are more likely to allow
their sense of worth to be based on how others view them. As a result,
they can be deeply afraid of the stigma of HIV. Homeless LGBT teens
already face terrible rejection from their families and communities.
They often find much of their self-esteem in their sexual desirability.
Being desired sexually is one of the very few areas where they feel
wanted and in control.
As a result, many of these young people
will refuse to return to a program where the staff or other clients
know they have HIV. Often, when a young person is given a positive test
result, that's the last time she or he is seen at that program. In
addition to providing a barrier to testing, this refusal to be seen by
others as HIV positive also creates a barrier to housing designed for
people with HIV. They think living there "outs" them in the eyes of
others.
What needs to be done to address this problem?
Kate:
It's essential that youth with HIV have access to stable housing so
that they can consistently participate in health care and support
services, eat nutritionally sound meals, get adequate amounts of rest,
and avoid the daily stress of trying to find somewhere safe to sleep.
The current New York City policy of restricting HIV/AIDS Services
Administration (HASA) housing to people with an AIDS diagnosis greatly
affects young people, since they are usually recently infected. This
policy forces them to remain homeless until factors related to their
homelessness interfere with their treatment to such an extent that they
develop AIDS and are finally eligible for HASA housing.
Carl:
Efforts to provide care for HIV-positive youth work best with a full
range of services, so the program is not stigmatized as HIV-specific.
Homeless LGBT youth are at such high risk of HIV infection because of
the catastrophic merging of risk factors that homelessness adds to
their lives. Addressing their homelessness is an important first step
toward HIV testing and care. The terrible lack of safe and appropriate
emergency housing for homeless LGBT youth is a public health crisis
that we must address if we ever hope to stem the spread of HIV.
http://www.thebody.com
|
Crazy ’House’
A
panel discussion about a controversial AIDS documentary, House of
Numbers, descended into a screaming match April 21 at the Boston
International Film Festival, with both the film’s director, Brent
Leung, and other members of the audience shouting down and attempting
to drown out the remarks of Dr. Daniel Kuritzkes, an HIV expert and
Harvard Medical School professor who was interviewed in the film.
April 22, 2009
Dr. Daniel Kuritzkes (second from left), a professor at Harvard Medical
School, told the audience at the screening that Leung’s film gave
unwarranted credibility to the AIDS denialist movement, and he accused
Leung of taking his own comments out of context in the film. Kuritzkes
was joined by fellow panelist and Fenway Health President and CEO
Stephen Boswell (left), as well as (right to left) Liam Scheff and
Christopher Fiala, two audience members who sat at the table uninvited
and claimed that they were providing balance to the panel.
(Source:Marilyn Humphries)
A panel discussion about a
controversial AIDS documentary, House of Numbers, descended into a
screaming match April 21 at the Boston International Film Festival,
with both the film’s director, Brent Leung, and other members of the
audience shouting down and attempting to drown out the remarks of Dr.
Daniel Kuritzkes, an HIV expert and Harvard Medical School professor
who was interviewed in the film.
Many of the
audience members who attempted to silence Kuritzkes were supporters of
a fringe movement known as AIDS denialism, which consists of people who
argue that the HIV virus either is not the cause or not the sole cause
of AIDS. While AIDS denialism has been roundly rejected as bogus
science by the mainstream scientific and medical community, House of Numbers suggests that there is still a robust debate about the cause of AIDS,
the existence of HIV, and the validity of HIV testing. Kuritzkes used
his remarks to try to debunk the denialist movement, and he is one of
more than a dozen scientists interviewed in the film who have signed
onto a statement rejecting AIDS denialism and claiming that they were
misled about Leung’s intentions in making the film.
Leung and
the denialists in the audience at the AMC Loews Boston Common theater
vocally objected to the format of the panel discussion even before it
got underway. The panel, organized by Amit Dixit -- a board member of
Massachusetts Area South Asian Lambda Association (MASALA) -- in
conjunction with Fenway Community Health and the festival organizers,
included Kuritzkes and Fenway president and CEO Dr. Stephen Boswell.
Kevin Cranston, head of the Massachusetts Department of Public Health’s
Bureau of Infectious Disease, served as moderator, and Cranston invited
Leung to participate as a panelist, although Leung elected to remain in
the audience.
As Kuritzkes began reading from a prepared
statement two members of the audience who appeared in the film walked
down to the front of the theater, sat beside Boswell and Kuritzkes at
the panelists’ table and refused to leave. Those audience members,
Christian Fiala, an Austrian gynecologist, and Liam Scheff, identified
in the film as a freelance journalist, both claimed that they were
forcibly joining the panel to provide balance. In the middle of
Kuritzkes’s speech Leung and several other audience members shouted
over him, "This is not a panel!" and, "Where’s the panel?" The shouting
reached a fever pitch when Kuritzkes began reading a list of names of
AIDS denialists who allegedly died of complications from AIDS.
"This
is an exercise in free speech," said Cranston, attempting to quiet the
crowd. "Dr. Kuritzkes is speaking. After he has completed speaking we
will open up for free dialogue. We can only do this if one person
speaks at a time. Shouting people down is not dialogue."
Several
audience members continued shouting over Kuritzkes’s remarks despite
Cranston’s admonition. Cranston warned audience members that anyone who
continued to interrupt the program would be asked to leave. A police
officer was present inside the theater, but he did not directly
intervene, and Fiala and Scheff remained seated at the panelists’ table
for the rest of the program.
Fair and balanced?
Leung’s
film followed his personal journey to London, Germany, South Africa and
the United States (Leung is Canadian) talking to a mix of scientists
and health officials as well as AIDS denialist activists like Fiala,
Scheff, and freelance journalist Celia Farber, who wrote a
controversial 2006 article in Harper’s Magazine that was widely
accused of promoting the denialist cause. The film included an
interview with Peter Duesberg, a University of California-Berkeley
molecular biology professor and arguably the most famous AIDS
denialist. Leung also interviewed Christine Maggiore, founder of the
denialist group Alive and Well. Maggiore was HIV-positive but denied
the link between HIV and AIDS; she died last December. Maggiore’s
supporters claim that her death was unrelated to AIDS, but a copy of
her death certificate posted on AIDStruth.org, a site aimed at opposing
the AIDS denialist movement, lists the cause of death as disseminated
herpes viral infection and bilateral bronchial pneumonia, AIDS-related
opportunistic infections. An L.A. Times obituary of Maggiore reports that her three-year-old daughter died in 2005 of AIDS-related pneumonia.
The
film also included interviews with luminaries in the field of HIV/AIDS
research, including Robert Gallo and Luc Montagnier, credited as
co-discoverers of the HIV virus, Peter Piot, former executive director
of UNAIDS, and Anthony Fauci, director of the National Institutes of
Allergy and Infectious Diseases at the National Institutes of Health
(NIH).
In his narration of the film Leung claims that his goal
is to present an unbiased view of the state of HIV research, but his
film suggests that certain key facts about HIV/AIDS that have been long
settled in mainstream scientific circles are still in dispute. During a
segment about the beginnings of the AIDS crisis among gay men in the
United States Kary Mullis, a leading AIDS denialist and a Nobel
Prize-winning chemist, blamed many early AIDS cases on poppers, saying,
"What exactly caused Kaposi’s sarcoma? We know that now. It was amyl
nitrite."
Former Sunday Times health reporter Neville
Hodgkinson, who wrote several articles questioning the link between HIV
and AIDS, says in the film, "The lifestyle explanation proved
politically unacceptable, but the virus explanation proved very, very
acceptable to many different parties."
In another section
Duesberg claims that many of the symptoms of AIDS were in fact caused
by the drugs used to treat the syndrome. Several people interviewed in
the film question the effectiveness of HIV tests. Ostensibly to provide
balance the film also includes interviews with people rebutting the
AIDS denialists’ arguments, but there is minimal discussion of the
reasons why mainstream scientists have largely written off the
denialists’ claims as junk science. During one interview Duesberg says,
"They’re all prostitutes, most of them, my colleagues."
At the film’s end Leung suggests that the cause of the global AIDS epidemic is poverty, not the HIV virus.
"At
journey’s end I find myself perplexed, bewildered at times with an
overall feeling of dismay and sadness. I found a research community in
disarray over the most fundamental understanding of HIV, all the while
presenting a monolithic public posture of authority and certainty.
Bluntly stated, we have tests that prove nothing, remedies that kill,
and statistics manipulated to the point of absurdity," Leung says.
"Ninety percent of global HIV corresponds to areas of great poverty and
squalor. Ironically, while we may have been pursuing a phantom killer,
a shape-shifting assassin, perhaps the real enemy has been hiding in
plain view, clear as day and as old as time."
During a post-film
question-and-answer session held before the panel Leung claimed that
his film took a neutral stance on the question of what causes AIDS. He
declined to say which side he represents.
"The purpose of the
film is to present a broad range of ideas, and those ideas are for you,
the audience, and for scientists to take and to create a catalyst for
more discussion," said Leung.
One audience member asked Leung
who funded the film, noting that Leung seemed to have a large budget
for travel. Leung declined to name the sources but described them as a
group of "funders from all over the world." When Bay Windows later asked him if most of his funders supported the viewpoint of AIDS denialists, Leung claimed that they did not.
Filmmaker versus subject
Once
the panel discussion got underway and Cranston succeeded in getting the
audience under control, Elizabeth Ely, an audience member affiliated
with the denialist group Rethinking AIDS, asked Kuritzkes what remarks
in the film had been taken out of context. Kuritzkes said his own
remarks in the film had been presented in a misleading light. During
the film there is a brief clip of Kuritzkes saying that in the early
days of the epidemic the standard dosage of the AIDS drug AZT was
likely too high. The clip follows comments by Duesberg blaming AZT for
many of the symptoms of AIDS.
"I can give you an example of my
own quotation where I was quoted very briefly in talking about how
early doses of AZT were toxic and that was the end of the statement,
but in a broader discussion about anti-retroviral therapy, as I recall,
the issue is really that the drugs have improved over time, the drugs
have become less toxic, and the treatments today are highly effective,
which is why we’ve seen an 80 percent reduction in mortality from HIV,"
said Kuritzkes.
Leung jumped in and told the crowd, "I would
like to add that was not taken out of context. Antiretrovirals are a
separate part of the film. AZT is one part of the film."
Kuritzkes replied, "AZT is an antiretroviral, unfortunately."
Kuritzkes
is one of several scientists featured in the film who have since come
forward and argued that they were interviewed for the film under false
pretenses and that they believe House of Numbers promotes an
AIDS denialist agenda. John Moore, a professor at Weill Medical College
of Cornell University, drafted a statement signed by himself and 15
others interviewed for the film, including Kuritzkes, Gallo and Piot,
alleging that the film "presents the AIDS denialist agenda as being a
legitimate scientific perspective on HIV/AIDS, when it is no such
thing. [Leung’s] film perpetuates pseudo-science and myths."
Moore, who was not present at the screening, told Bay Windows he and several other scientists interviewed for the film first came in
contact with Leung through Martin Delany, the pioneering AIDS activist
and executive director of Project Inform who passed away in January.
Delany was interviewed for the film, and Moore said Delany vouched for
Leung as a legitimate filmmaker. Moore said Leung interviewed him on
two successive occasions, once in 2006 and again a year later, and said
Leung told him the goal of his film was to document the history of AIDS
research and to expose the lies behind the denialist movement. Several
weeks ago Moore said Leung e-mailed him and other film participants a
link to the film trailer, and Moore was shocked to find that the film
seemed to present a sympathetic portrait of denialists.
"I
didn’t know he lied until I saw the trailer," said Moore, who said
watching the trailer prompted him to draft his statement and contact
the other film participants to ask them to sign it. He has not seen the
film, which debuted at the Nashville Film Festival April 19 and has
only screened in Nashville and Boston, but he said based on the trailer
and conversations he has had with people who have attended the
screenings he believes the film falls squarely in the denialist camp.
Leung told Bay Windows that he was up front with Moore about the subject of his film. He said
he told Moore that the film was a documentary on public awareness about
HIV and AIDS, about AIDS education and testing and other issues
relating to the epidemic. He also said that since Moore had authored a
2006 New York Times op-ed opposing the denialist movement
entitled "Deadly Quackery," he wanted "to address whether HIV is the
cause of immune deficiency. And that was the extent that I told him it
was about." He said he believes some of the scientists who signed
Moore’s statement were upset because the film allegedly shows them
making contradictory statements about the nature of HIV and AIDS.
What’s at stake
During
the panel discussion Boswell told the denialists in the crowd, "It’s
important to know there’s a lot at stake. If you’re wrong and HIV does
cause [AIDS] you’re doing a profound disservice to our race."
Ely responded from the audience, saying, "And if you’re wrong you’re doing a profound disservice. That’s our point."
Boswell
replied, "Science has a way, a system for testing new ideas, and if you
have an idea that’s different then you can present those ideas, you can
test them in a scientific way, present your findings in a peer-reviewed
journal, have another laboratory verify what you say happened. I
haven’t seen any of that happen in any of this work. All I know is that
we test for HIV in the blood supply and over a period of three years
transfusion-transmissible AIDS virtually disappeared in the United
States. We start testing women for the HIV virus who are pregnant, and
we virtually eliminate AIDS in children. In 1995 I give a cocktail of
medications to patients who are within weeks of dying, and those
patients a few weeks later have gained 10, 20 pounds, and some of them
are alive today."
Following the panel Leung told Bay Windows that he nearly pulled the film from the festival 15 minutes before the
screening. He said festival organizers had promised him that there
would be a "two-sided" panel discussion, and he objected to the
selection of Cranston as moderator, calling him "obviously biased to
one side" because of his work on HIV/AIDS in the public health sector.
Asked
if his film was designed to spread the message of the AIDS denialist
movement Leung said, "I don’t feel strongly about getting their message
out. I feel strongly about freedom of speech. As I’ve gone around the
world interviewing these world scientists who set the foundation for
everything we know about HIV and AIDS and continue to set the
foundation in policies, I found that there’s a lot of disconnect
between what they say, there’s a lot of contradiction, there’s a lot of
confusion, and people are dying. So it doesn’t matter who says what,
what arguments come from each side. We have to have an open dialogue.
We need to know why people are dying."
The film festival
released a statement saying that the goal of the post-film panel was to
create a venue for members of the community to respond to the film.
"The
Boston International Film Festival never intended to host a formal
debate about the film; we intended to provide a forum in which members
of the community could engage with, and respond to, the film. It was a
difficult decision to screen ’House of Numbers,’ and we are very
pleased that the director, Brent Leung, attended the screening and
answered questions about his film," read the statement in part.
The
statement goes on to say that there was some miscommunication between
festival organizers and the filmmaker about the format of the panel
discussion but that the festival decided to go forward with the panel
"to create an opportunity for healthy social discourse."
The
statement also says the festival requested the presence of a police
officer at the screening in response to concerns about security.
"In
anticipation of the event, we were concerned about security and we
believed it was very important to have a visible police presence at the
screening; Security issues were also considered in how the situations
were handled. ...We are issuing this statement so that other festivals
can be aware of the potential for escalated actions, and that the other
festivals can be extremely diligent in their planning so that future
screenings can be executed in a safe and constructive manner."
Chloe
McFeters, public relations manager for the festival, declined to
elaborate on what prompted concerns about security. Dixit, who worked
with the festival organizers to organize the panel discussion, said the
festival requested a police officer because an AIDS denialist with a
past history of violent actions and run-ins with the law had posted on
the Internet that he would attend the Nashville screening, and the
Boston festival organizers were concerned he would attend the Boston
screening as well.
Dixit said that he believes the film presents
a biased perspective in favor of the AIDS denialists, and the goal in
selecting Boswell and Kuritzkes as the panelists was to bring in
respected members of the local scientific community to present their
response to the claims laid out in the film.
"I said [to the
filmmakers during the planning process] you have 87 minutes, and then
the director Q&A, but for me to put these people on the same panel
[the night of the screening] who barged up, who have no credentials,
it’s an absolute insult to the people we know, it’s an insult to
Boswell and Dan who have been doing this for years. ... Fenway, myself,
we were about creating a scientific dialogue, that was what the whole
premise was," said Dixit.
He said he was frustrated that the denialists in the audience seemed intent on drowning out the panelists.
"For
me I was very disappointed in not being able to hear the experts. Dan
spoke eloquently and he answered the questions right on. I was very
proud to have our heroes onstage," said Dixit. "But I was very
disappointed. What we tried to do was create a scientific dialogue. It
was interrupted by denialists in the audience who were very aggressive,
and they couldn’t engage in a civil manner to our experts."
By Ethan Jacobs, http://www.baywindows.com
|
Curb Aids and HIV by decriminalising drugs, say experts
In
an unprecedented attack on global drugs policy, Michele Kazatchkine,
head of the influential Global Fund to Fight Aids, Tuberculosis and
Malaria, has told the Observer that, without a radical overhaul of laws
that lead to hundreds of thousands of drug users being imprisoned or
denied access to safe treatment, the millions of pounds spent on
fighting HIV and Aids will be wasted.
April 19, 2009
Aids and HIV worldwide. Photograph: Cat Davison/Pete Guest
The use of illicit drugs must be decriminalised if efforts to halt the spread of Aids are to
succeed, one of the world's leading independent authorities on the
disease has warned.
In an unprecedented attack on global drugs
policy, Michele Kazatchkine, head of the influential Global Fund to
Fight Aids, Tuberculosis and Malaria, has told the Observer that,
without a radical overhaul of laws that lead to hundreds of thousands
of drug users being imprisoned or denied access to safe treatment, the
millions of pounds spent on fighting HIV and Aids will be wasted.
Kazatchkine
will use his keynote speech at the 20th International Harm Reduction
Association conference tomorrow in Bangkok to expose the failures of
policies which treat addiction as a crime. He will accuse governments
of using what he calls "repressive" measures that deny addicts human
rights rather than putting public health needs first.
He will
argue that governments should fully commit to the widespread provision
of harm reduction strategies aimed at intravenous drug users, such as
free needle exchanges and providing substitutes to illicit drugs, such
as methadone.
"A repressive way of dealing with drug users is a
way of facilitating the spread of the [HIV/Aids] epidemic," Kazatchkine
said. "If you know you will be arrested, you will not go for treatment.
I say drug use cannot be criminalised. I'm talking about criminalising
trafficking but not users. From a scientific perspective, I cannot
understand the repressive policy perspective."
He condemns
policymakers who argue that, because drug users frequently turn to
crime to fund their habit, it justifies making it a criminal justice
issue. Harm reduction both helps the addict and wider society and
reduces the need to commit crime, he said.
"The one population
where [Aids] mortality has been untouched - and in fact has worsened -
has been IV [intravenous] drug users. It's amazing, because what we
call harm reduction, such as exchanging needles, has been
scientifically proven as the most effective.
"This is why I will
most probably start my speech in Bangkok by mentioning the contrast
between major progress achieved in decreasing mortality from Aids in
the poorest countries of the world versus the total lack of progress
for what is the main route of transmission in most parts of the world
outside Africa."
Kazatchkine suggested that politicians feared
that the public would label them soft on drugs. A doctor and respected
Aids expert with 20 years in the field, he has in his two years at the
helm of the Global Fund overseen some of the most dramatic improvements
in treatment and prevention of HIV globally.
Since it was
established in 2001, the fund has received $21bn in contributions from
the world's wealthiest nations and used it to play a significant part
in reducing rates of new HIV infections. It has also contributed to the
distribution of much needed life-preserving anti-retroviral drugs to
millions of people already diagnosed.
Alex Stevens, a senior
research fellow specialising in drugs and criminalisation at the
University of Kent, said tomorrow's speech would highlight many of the
troubling consequences of criminal justice approaches to drugs policy.
"In
many countries, serious human rights infringements are committed in the
name of fighting drugs," he said. "These include the use of the death
penalty for drug offences, compulsory treatment regimes that include
methods (such as physical beatings) that are akin to torture, and, for
example in the USA, depriving convicted drug law offenders of the right
to vote."
Stevens said that, while the UK was ahead of many
other countries on harm reduction, its tendency to criminalise drug
users could undermine its efforts.
What is needed, Kazatchkine
will argue tomorrow, is a total rethink of drugs policies. "What I'm
saying is that government's function is to protect their citizens. This
is why harm reduction should be supported by all governments
everywhere."
by Mary O'Hara with Additional research by Ali Ahmad, http://www.guardian.co.uk
|
Brits with HIV 'still being refused entry to US"
Terrence
Higgins' Trust states it has received calls from people who used the
online visa system and believed they were permitted to travel but were
turned away at US border controls, incurring substantial travel
expenses. Lisa Power, head of policy at THT, said: “While we are
pleased that the US government intend to revisit their entry
regulations, it has not happened yet.
April 20, 2009
Those with HIV have been warned they must ensure
they are legally allowed to travel
People
living with HIV are still being refused entry to the US, despite
government plans to change legislation, it has been claimed.
According
to the Terrence Higgins Trust (THT), those with HIV who want to travel
to the US must attend an interview at the American Embassy in London
before they can travel legally.
A new online visa waiver system was set up recently, but those who have HIV must still have a special visa.
Currently, people with HIV are permanently excluded from the United States except in exceptional circumstances.
Following
new legislation last year, the HIV entry ban is no longer law, but
remains an administrative decision to be ruled on by the Department for
Health and Human Services.
THT states it has received calls
from people who used the online visa system and believed they were
permitted to travel but were turned away at US border controls,
incurring substantial travel expenses.
Lisa Power, head of
policy at THT, said: “While we are pleased that the US government
intend to revisit their entry regulations, it has not happened yet.
"People with HIV shouldn't jump the gun by assuming it's already okay to travel to the US without a special visa.
"Everyone
entering the US is still required to state that they have no
transmissible conditions, alongside not being a terrorist, a Nazi or a
criminal.
"People who don’t get the special visa but then
disclose their status on entry run the risk of being forcibly deported
and banned from entering the US again, so please be aware of the rules
before you fly.”
People living with HIV who would like further
information on their right to travel internationally can contact THT
Direct on 0845 1221 200 from 10am to 10pm weekdays and from 12pm to 6pm
weekends, or email info@tht.org.uk.
Related Articles
HIV stigma "fuels homophobia and discrimination"
HIV rates in gay men still at high levels
One-third of HIV sufferers 'face discrimination'
Gay men in Jamaica 'face higher levels of HIV due to discrimination'
http://www.pinknews.co.uk
|
Female Condom Approval Raises Hopes for Global Use
An
early version of the female condom was introduced in 1993, and it
remains the only available woman-initiated form of protection against
both STDs and unintended pregnancy. Yet despite global promotion by the
United Nations and other organizations, its usage is still minuscule,
even as women bear an ever-growing share of the AIDS epidemic.
Advocates hope the dynamics will change following last month's approval
by the Food and Drug Administration of the FC2, a new version of the
female condom produced by Chicago-based Female Health.
April 20, 2009

Advocates of the female condom are promoting a less costly,
more user-friendly version that they hope will vastly expand its role in the global fight
against HIV and other sexually transmitted diseases.
RELATED ARTICLES
FDA Approves Female Condom
Advocates Tout Female Condoms
Women Demand Access to Female Condoms
An
early version of the female condom was introduced in 1993, and it
remains the only available woman-initiated form of protection against
both STDs and unintended pregnancy. Yet despite global promotion by the
United Nations and other organizations, its usage is still minuscule,
even as women bear an ever-growing share of the AIDS epidemic.
Advocates hope the dynamics will change following last month's approval
by the Food and Drug Administration of the FC2, a new version of the
female condom produced by Chicago-based Female Health.
About 35
million female condoms were distributed worldwide last year, but that
compares to more than 10 billion male condoms, which are far cheaper
and, at least initially, easier to use. However, in some nations with
high HIV rates, many men refuse to wear condoms, putting women at risk.
Though it looks similar to its predecessor -- a soft, transparent
sheath with flexible inner and outer rings -- the FC2 is made from
synthetic rubber rather than polyurethane, making it cheaper to
produce.
Mary Ann Leeper, former president of Female Health and now its
strategic adviser, said the FC2 also is less noisy during use.
Complaints about squeaky noises were among the factors that slowed
acceptance of the original version.
The cost of the FC2 is one
third less than its predecessor, and may go lower, enabling health
organizations to distribute many millions more than at present. For
now, the price is about 60 cents, compared to less than 4 cents for
mass-distributed male condoms -- a difference that's an issue in the
developing world.
The FC2 had been accepted previously by some
international organizations, and Female Health distributed 14 million
of them abroad last year along with 21 million of the older version.
Advocates of the female condom praised the FDA announcement because it
opens the door for the U.S. Agency for International Development
(USAID), one of the largest global providers of condoms, to distribute
the FC2 overseas.
"This is a tremendous victory," said Susie
Hoffman, an assistant professor of clinical epidemiology at Columbia
University who contends the female condom has suffered from
misconceptions. "In the United States, there has been strong bias
against it," Hoffman said. "Some people involved in AIDS and family
planning would say, 'Why do we need these? ... It's so weird that women
are not going to pick it up.' But if presented in the right way, many
women do like it. To find these people and help them and train them,
you need systematic programming, which costs money."
Resistance
is less of a problem in some developing nations. The United Nations
Population Fund, government agencies, and nonprofits are aggressively
promoting female condoms in places such as Brazil, Ghana, Zimbabwe, and
South Africa.
Women's groups in Zimbabwe collected more than
30,000 signatures demanding access to the female condom. In Ghana,
nonprofits say more than 10,000 people have attended training programs
that teach women how to insert female condoms -- they require careful
instruction to be used properly -- and how to negotiate with their male
partners.
"The mind-set is changing, but there are still a lot
of challenges," said Bidia Deperthes, the Population Fund's HIV
technical adviser for condoms. "Accessibility is still minimal. There's
a huge demand, and we're not meeting it."
Deperthes hopes that
with FDA approval of the FC2, the number of female condoms distributed
globally could climb to 50 million this year. If the numbers keep
rising, she said, the cost to public-sector distributors for each FC2
could drop as low as 25 cents.
Jeff Spieler, a science adviser
with USAID's Office of Population and Reproductive Health, said the
female condom's future may depend on whether its promoters can develop
a private-sector market. Its commercial price in the United States
generally has been more than $2.
Another challenge is a stigma
associated with the female condom in some places because prostitutes
are among those deemed to benefit most from using it. On the other
hand, advocates of the female condom say it has invaluable safer-sex
potential for married women whose husbands are unfaithful and shun male
condoms.
Serra Sippel, executive director of the Center for
Health and Gender Equity in Washington, D.C., said the FDA approval of
the FC2 is a key step toward "putting the power of prevention in
women's hands." But she bemoaned the product's limited over-the-counter
availability. “We'd love to see the profile raised, to have commercials
about it and normalize it so people aren't embarrassed," she said.
Mary Ann Leeper said Female Health is seeking a corporate partner to
help market the FC2. She suggested that concern about HIV may generate
interest among women in communities with high infection rates.
The female condom's advocates stress that it will never be the "magic
bullet" that by itself turns the tide in fighting AIDS. But, they say,
it should be a bigger part of the arsenal.
"It's not going to be the one answer," Hoffman said. "But it's got a lot more to contribute than it has to date.”
[This report reprinted with permission of the Associated Press. (c) 2009 by Associated Press | David Crary | April 16, 2009]
http://www.hivplusmag.com
|
German AIDS Group Endorses HIV Treatment as Prevention
A
premier German nongovernmental organization (NGO) is endorsing
antiretroviral medication as an effective form of HIV prevention,
mirroring last year’s Swiss statement on the lowered risk of
transmission from positive people on treatment to their negative
partners, aidsmap.com reports.
April 22, 2009
A
premier German nongovernmental organization (NGO) is endorsing
antiretroviral medication as an effective form of HIV prevention,
mirroring last year’s Swiss statement on the lowered risk of
transmission from positive people on treatment to their negative
partners, aidsmap.com reports.
Researchers from the Swiss Federal Commission for HIV/AIDS said that HIV-positive people on meds and with undetectable viral loads
for six months and no sexually transmitted infections (STIs) cannot
transmit the virus through heterosexual sex.
According to the article, Deutsche AIDS-Hilfe calls transmission in
such circumstances “unlikely” and claims that antiretroviral treatment
is as effective as condom use in preventing infection in negative
partners.
In a position paper, Deutsche AIDS-Hilfe says that sexual HIV
transmission is unlikely when the HIV-positive partner’s viral load has
been undetectable for at least six months, the person is adhering to
antiretroviral therapy and there is no damage to the mucous membranes.
In those circumstances, the NGO says, the risk of transmission is
negligible and, when combined with condom use, is close to zero.
http://www.poz.com
|
Significant reductions in price of first- and second-line HIV treatment thanks to UNITAID and Clinton deal
HIV
treatment consisting of just one pill, once a day, will be available in
poorer countries at a cost of $210 per patient, per year, thanks to an
agreement announced by UNITAID and the Clinton HIV/AIDS Initiative.
April 17, 2009
HIV treatment consisting of just one pill, once a day, will be
available in poorer countries at a cost of $210 per patient, per year,
thanks to an agreement announced by UNITAID and the Clinton HIV/AIDS
Initiative. The price of boosted protease inhibitor-based second line
HIV treatment will also falls significantly to an annual cost per
patient of $590.
Deals were struck by UNITAID and the Clinton
Initiative with generic manufacturers to enable these price cuts.
Thanks to the deals there is a 17% reduction in the price of the most
affordable second-line antiretroviral combination of 3TC, tenofovir and
ritonavir-boosted lopinavir for the world’s poorest countries.
Heat-stable lopinavir/ritonavir will be available at a maximum cost of
$470 per patient, per year. Generic versions of atazanavir and
heat-stable ritonavir are expected to yield further price decreases.
UNITAID funded projects in 42 poorer countries will benefit from the
reductions in the cost of second-line treatment. They will also be
available to over 70 developing countries that are members of the
Clinton HIV/AIDS Initiative’s Procurement Consortium, as well as being
extended to participants in the Global Fund’s Voluntary Pooled
Procurement scheme.
More tolerable and convenient first-line HIV
treatment will also become more affordable thanks to new price
agreements. A single pill that combines HIV treatment consisting of
3TC, tenofovir and efavirenz in a single pill taken once a day will be
available for an annual per patient cost of $210. This price compares
with a maximum cost of $89 a year for a fixed dose combination of d4T,
3TC and nevirapine, which is taken twice daily. This represents a
reduction of 30% on prices agreed by UNITAID and the Clinton Initiative
in 2008, and is over a third lower than the average cost of this
combination in low-income countries.
The latest agreements between
UNITAID and the Clinton initiative will bring down the price of 41
adult and paediatric formulations of anti-HIV drugs. The new prices are
on average 16% lower than the lowest prices in 2008. Since 2007 UNITAID
and Clinton deals have helped bring about a 62% reduction in the price
of first-line HIV therapy for the world’s poorest countries hardest hit
by HIV. Price reductions for second-line treatment are projected to
bring annual savings of $100 million.
By Michael Carter, http://www.aidsmap.com
|
“Quad” HIV Pill Enters Phase II Study
Gilead
Sciences Inc. announced today it initiated a Phase II study of a new
four-in-one—or “Quad”—HIV treatment. The Quad pill includes Gilead’s
experimental integrase inhibitor called elvitegravir, an experimental
boosting agent called GS 9350 and the approved drugs Viread (tenofovir)
and Emtriva (emtricitabine).
April 20, 2009
Gilead Sciences Inc. announced today it initiated a Phase II study of a new four-in-one—or “Quad”—HIV
treatment. The Quad pill includes Gilead’s experimental integrase
inhibitor called elvitegravir, an experimental boosting agent called GS 9350 and the approved drugs Viread (tenofovir) and Emtriva (emtricitabine).
The
study will enroll 75 HIV-positive people who’ve never taken
antiretroviral therapy before and will randomize them to take either
the Quad pill or Atripla (efavirenz, tenofovir and emtricitabine). The 48-week trial will
determine both the efficacy and the safety of the Quad pill after 24
and 48 weeks of treatment.
The study is not so much to evaluate
the efficacy and safety of elvitegravir—which has already successfully
completed a Phase II study and is now in two large Phase III studies—as
much as to test the new blood level boosting agent GS 9350, which is
being examined as an alternative for low-dose Norvir (ritonavir).
http://www.poz.com
|
CD4 cell counts becoming lower soon after infection with HIV, suggests virus becoming more virulent
“We
observed that initial CD4 cell count among documented HIV
seroconverters in the United States significantly decreased during the
HIV epidemic,” write the investigators. This decline reached a plateau
after the use of antiretroviral therapy became widespread. The
investigators speculate that the fall in initial CD4 cell counts was
likely to be because HIV had evolved to become more virulent.
April 21, 2009
The initial CD4 cell counts of patients newly infected with HIV fell
significantly between 1985 and 2001, US research published in the May 1st edition of Clinical Infectious Diseases has shown. This suggests that the virus may have evolved to become more
virulent during this time period, which could have clinical
implications, shortening the interval between infection with HIV and
the need to start HIV treatment.
In people with HIV, CD4 cell counts provide an important indication of
the strength of the immune system, of HIV disease progression and of
when to start antiretroviral treatment.
At the time of HIV infection a massive loss of CD4 cells occurs.
The immune system then mounts a response to HIV, virus levels fall, and
the CD4 cell count recovers - although often it fails to return to
levels seen in healthy individuals. The CD4 count soon after infection
with HIV is a strong indicator of the subsequent risk of disease
progression: in cases where the CD4 count stabilises at a level below
350, an individual has a higher short-term risk of disease progression.
It is generally assumed that there will be an interval of several
years between initial infection with HIV and a fall in CD4 cell count
to such levels that the initiation of HIV treatment is warranted.
However, there is some evidence in recent years of patients having lower CD4 cell counts shortly after their infection with HIV, and of more rapid disease progression, requiring HIV treatment soon after diagnosis.
US investigators therefore analysed the initial CD4 cell counts of
patients recently infected with HIV between 1985 and 2007. The study
population was racially diverse and came from HIV treatment centres
across the country.
A total of 2174 people were included in the investigators’ analysis.
All had had an HIV-negative test result at most four years before their
diagnosis with HIV.
The mean age was 29 years; 96% were men; 45% were African American, 44% white and 11% other ethnicities.
Just over a third (35%) were diagnosed with HIV within a year of a
previous negative test result, 41% were diagnosed within one to two
years of testing HIV-negative, 17% within two to three years, and 7%
within three to four years. A CD4 cell measurement was taken within
three months of HIV diagnosis in 90% of patients.
Changes in initial CD4 cell count were examined in four separate time
periods: 1985 to 1990; 1991 to 1995; 1996 to 2001; and 2002 to 2007.
Between 1985 and 1990, the mean initial CD4 cell count of individuals recently infected with HIV was 632 cells/mm3. This fell to a mean of 553 cells/mm3 for the period 1991 and 1995, and to a mean of 493 cells/mm3 between 1996 and 2001. The figure then stabilised at a mean of 514 cells/mm3 between 2002 and 2007.
The fall in initial CD4 cell count between the period 1985 and 1990 and
1991 to 1995 was highly significant (p < 0.001), as was the fall
between this period and 1996 and 2001 (p < 0.001).
Further analysis showed that the proportion of individuals with an initial CD4 cell count below 200 cells/mm3 (an AIDS diagnosis), and 350 cells/mm3, the point at which it is now recommended to start antiretroviral therapy, increased significantly between 1985 and 2001.
The investigators then conducted statistical analysis to control for
possible confounding factors. This showed that compared to the period
1985 to 1990, initial CD4 cell count was 65 cells/mm3 lower in the period 1991 to 1995 (p < 0.001), 107 cells/mm3 lower in the period 1996 to 2001 (p < 0.001) and 102 cells/mm3 lower in the period 2002 to 2007 (p < 0.001).
Similar declines were observed in initial CD4 cell percentage: from 30%
in the period 1985 to 1990 to 28% between 1991 and 1995, and 27% in
both the later time periods. Adjusted analysis showed that these falls
in CD4 cell percentage were significant in all time periods.
Finally the investigators analysed the possible effect of race on their
results. They found that in both African-American and white patients
initial CD4 cell count declined by a mean of 111 cells/mm3.
“We observed that initial CD4 cell count among documented HIV
seroconverters in the United States significantly decreased during the
HIV epidemic,” write the investigators.
This decline reached a plateau after the use of antiretroviral therapy
became widespread. The investigators speculate that the fall in initial
CD4 cell counts was likely to be because HIV had evolved to become more
virulent.
Reference
Crum-Cianflone N et al. Is HIV becoming more virulent? Initial
CD4 cell counts among HIV seroconverters during the course of the HIV
epidemic: 1985 – 2007. Clin Infect Dis 48: 1285-1292, 2009.
By Michael Carter, http://www.aidsmap.com
|
Isentress’s Prevention Potential
The
integrase inhibitor Isentress (raltegravir), when taken by either
HIV-negative or HIV-positive people, might be able to prevent HIV
transmission, according to a presentation at the International Clinical
Pharmacology Workshop in Amsterdam.
April 21, 2009
The integrase inhibitor Isentress (raltegravir), when taken by either HIV-negative or HIV-positive
people, might be able to prevent HIV transmission, according to a
presentation at the International Clinical Pharmacology Workshop in
Amsterdam.
Though Viread (tenofovir) and Truvada (tenofovir plus emtricitabine) are the leading antiretroviral (ARV)
treatments being tested for use in HIV-negative people to prevent HIV
infection, other ARVs are being considered for pre-exposure prophylaxis
(PrEP). Researchers have also begun studying whether treating
HIV-positive people, regardless of their CD4 count or medical need for
ARV therapy, might help them reduce the risk of transmitting HIV to
their HIV-negative partners.
One of the primary questions with
using a specific ARV with either strategy is how well the drug reaches
and accumulates in the genital tract compared with the blood stream.
Researchers speculate that if an HIV medication does not easily
penetrate the genital tract—the initial site of infection for many
exposed to the virus and a reservoir for HIV among those living with
the virus—it may not be the best choice for prevention purposes.
To
determine genital tract distribution with Isentress, Amanda Jones,
PharmD, from the University of North Carolina in Chapel Hill, and her
colleagues studied blood and genital levels of Isentress in seven
HIV-negative women. All of the women took Isentress twice daily for six
days and once in the morning on the seventh day. They began taking
their first dose between five and seven days after completing their
last menstrual period.
Jones’s team found that Isentress levels
took longer to build up in the genital tract following the first dose
than in the blood, but after multiple doses Isentress levels stayed 93
percent higher in the genital tract than in the blood. This is lower
than a few drugs such as Selzentry (maraviroc), which reaches genital levels more than 400 percent higher
than in blood, but roughly comparable with Viread. What’s more,
Isentress levels lasted nearly two and a half times longer in the
genital tract than in blood.
The authors suggest that Isentress
might be a promising candidate for PrEP. They also state that
HIV-positive people who take Isentress might be less likely to pass HIV
on to others through sexual contact due to high concentrations of the
drug in the genital tract.
http://www.aidsmeds.com
|
Taming a deadly disease
There is still no vaccine and no cure, but 25 years after AIDS was discovered, sufferers are no longer dying from the virus
April 22, 2009
Twenty-five years after the discovery of the AIDS virus, the deadly
disease has been halted in its tracks – so much so that sufferers are
now dying at a ripe old age.
Nearly 85 per cent of patients
being treated for HIV-AIDS with drug cocktails have undetectable levels
of virus in their bloodstream, according to new data from the B.C.
Centre for Excellence in HIV-AIDS in Vancouver.
“People with
HIV are not exempt from destiny,” Dr. Julio Montaner, the centre's
director, said in an interview, “but they are no longer dying from
AIDS.” That fact, he said, “really tells the story of how far we've
come with treatment.”
When Margaret Heckler, then
secretary-general of the U.S. Health and Human Services Department,
announced at a Washington news conference on April 23, 1984, that the
“probable cause” of AIDS had been found, she boldly predicted a vaccine
within two years and eradication of the disease by 1990.

Toronto activist Ron Rosenes
has been living with HIV for more than 25 years.
(Charla Jones/The Globe and Mail)
Related Articles
Recent
The greying of AIDS:
Profiles of Canadians who have been living with the disease for decades.
GLENN FASH, 59
LYNN KAMPF, 58
JOHN KOZACHENKO, 53
FERNANDO RODRIGUEZ, 46
If only it were so.
There is still no vaccine, no cure, and HIV-AIDS continues to spread
relentlessly, with 2.7 million new infections worldwide last year and
33 million people living with the virus.
The good news is
that scientists have learned to subdue the wily human immunodeficiency
virus: Powerful drug combos are used to shut down HIV replication and
limit the damage it inflicts on the immune system.
The impact
of this treatment regime, known formally as highly active
antiretroviral treatment (HAART), is undeniable – adding, on average,
13 years to the life expectancy of HIV-positive people, according to a
study by Robert Hogg of the B.C. Centre for Excellence in HIV-AIDS.
Virtually anyone with money – or access to a public-health system like
Canada's – can neutralize the virus's effects on the immune system and
have a normal life expectancy.
“There's no reason people
can't live 50 years with HIV,” said Anita Rachlis, an
infectious-diseases consultant at Sunnybrook Health Sciences Centre in
Toronto. “But people with HIV often have a lot of co-morbidities.”
Indeed, while survivors are living longer, they are also dealing with a
combination of related health challenges: the ravages inflicted on the
immune system by the virus over many years; the damage done by
long-term use of powerful drugs; and the effect of other infections
that came along for the ride with HIV (such as hepatitis, herpes and
HPV), not to mention the normal process of aging.
“I wonder
what's going to get me, but I don't think it's going to be AIDS,” said
Ron Rosenes, a Toronto activist who has been living with HIV since the
early days of the epidemic. Rather, he worries about anal cancer,
lymphoma and heart disease – which are common in long-time survivors
because of immune-system damage.
Like most Canadians with
HIV-AIDS, Mr. Rosenes takes a cocktail of three drugs to keep the virus
in check. He also takes medication to deal with some of the side
effects, including drugs for osteoporosis and acid reflux, and a
powerful vitamin and mineral supplement called K-PAX to bolster his
immune system. “I never thought I would live to 50, let alone 61,” Mr.
Rosenes said.
There is, in fact, a growing legion of people reaching their golden years with what was once a disease of the young.
“Treatment advances have transformed HIV from a death sentence to a
life sentence,” said Bill Cameron, president-elect of the Canadian
Association for HIV Research.
Dr. Cameron said medications
have evolved over time. At first they were used to control infections,
then drugs were combined to suppress the virus, and now those drugs are
being refined to be less toxic and better tolerated.
Years
ago, it was not uncommon for AIDS sufferers to take 40 to 50 pills a
day on complex timetables. These drugs would often cause severe
diarrhea and lipodystrophy – the abnormal distribution of fat – that
left people with buffalo humps on their backs, grossly distended
bellies and hollowed-out cheeks.
Today, many people can manage HIV-AIDS with a single daily pill with no visible side effects.
A bigger challenge than the treatment itself is getting people tested
and into treatment. Approximately 62,000 people in Canada are living
with HIV-AIDS, and about one-quarter of them are unaware of their HIV
status, the Public Health Agency of Canada says.
According to
the agency, men who have sex with men continue to make up the largest
chunk of newly infected people at 43 per cent, while heterosexuals
comprise another 25 per cent. Intravenous drug users account for 20 per
cent of new infections, and immigrants from countries where AIDS is
endemic account for 7 per cent. (The balance is made up of people whose
history of exposure to the virus is unclear.)
“AIDS is
increasingly a social disease. It's associated with disenfranchised
people,” Dr. Cameron said. These groups can be hard to reach so they
often do not benefit from treatment advances.
While the pace
of improvements in treatment and care can seem glacial to those who are
sick, the speed at which the virus that causes AIDS was discovered,
treatments developed and then widely used in the clinical setting (at
least in wealthy countries like Canada) is unprecedented.
The
virus was discovered in 1984; the first treatment, zidovudine (AZT),
was on the market in 1987. Triple cocktails made their debut in 1996,
and by 2006 there was a once-a-day pill. This happened in large part
because activists – gay men, victims of tainted blood and scientists –
pushed governments relentlessly to fund research. Those with HIV-AIDS
also offered themselves up as guinea pigs in clinical trials. Most of
the long-time activists are long-time survivors.
Janet Conners is a case in point.
The 53-year-old Halifax resident was for many years a public figure, a
woman who had contracted HIV from her hemophiliac husband who had been
infected by tainted blood products, and she fought tirelessly for
justice and compensation. But the disease took its toll: Ms. Conners
lost her husband to AIDS, becoming a widow at 37, struggled with the
effects of immune deficiency and of treatment, and, in 2001, had a
serious heart attack.
“These drugs have kept me alive but you
have to understand this is chemotherapy. It's hard on the body and on
the mind,” she said.
Like many long-term survivors, Ms.
Conners developed resistance to some medications, so she required
increasingly powerful substitutes. She is now on “salvage therapy” –
meaning she is running out of treatment options.
In addition
to heart problems, Ms. Conners suffers from neuropathy, the loss of
feeling in her extremities, along with muscle loss and weakening bones.
She takes upwards of 30 pills a day – the majority not for HIV any
more. “My pill box is my full-time job,” she said. It is also a
bittersweet mistress. “After 20 years of daily use, I have pill
burnout.”
But, for all the challenges, the treatment still
represents hope. Ms. Conners, who was given only a few years to live
when she was diagnosed in 1989, has survived longer than she ever
expected, has seen her son grow to adulthood, and has remarried.
“The meds are not a magic bullet,” she said. “But they've allowed me and many others to have a life.”
By Andre Picard, http://www.theglobeandmail.com
|
|
|